Home
Jennifer Gjerde's picture

Jennifer Gjerde

Postdoctoral Fellow
  • E-mailJennifer.Gjerde@uib.no
  • Phone+47 55 97 43 98
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2020). Validation and Determination of 25(OH) Vitamin D and 3-Epi25(OH)D3 in Breastmilk and Maternal- and Infant Plasma during Breastfeeding. Nutrients. 18 pages.
  • Show author(s) (2019). Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer. The Pharmacogenomics Journal. 1-8.
  • Show author(s) (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
  • Show author(s) (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Research and Treatment. 97-108.
  • Show author(s) (2015). The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. PLOS ONE. 19 pages.
  • Show author(s) (2015). Estrogens correlate with PELP1 expression in ER positive breast cancer. PLOS ONE. 12 pages.
  • Show author(s) (2014). Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults. Lipids in Health and Disease.
  • Show author(s) (2014). Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. European Journal of Oncology Nursing. 1-7.
  • Show author(s) (2013). Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
  • Show author(s) (2013). Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements. Obesity. 2495-2503.
  • Show author(s) (2013). A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research. 11 pages.
  • Show author(s) (2012). Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Research and Treatment. 693-700.
  • Show author(s) (2012). The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss. International Journal of Obesity. 1195-1202.
  • Show author(s) (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 12 pages.
  • Show author(s) (2011). Functional polymorphisms in UDP-glucuronosyltransferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiology, Biomarkers and Prevention. 1937-1943.
  • Show author(s) (2011). Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. The Pharmacogenomics Journal. 100-107.
  • Show author(s) (2010). Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clinical Cancer Research. 2176-2186.
  • Show author(s) (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 13 pages.
  • Show author(s) (2008). Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of Bone and Mineral Research. 1267-1277.
  • Show author(s) (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
  • Show author(s) (2007). Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. Journal of Clinical Oncology. 4201-4209.
  • Show author(s) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
  • Show author(s) (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 231-234.
  • Show author(s) (2005). Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. Journal of Steroid Biochemistry and Molecular Biology. 489-498.
  • Show author(s) (2005). Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A. 6-14.
  • Show author(s) (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. Clinical Cancer Research. 2336-2343.
  • Show author(s) (2003). Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 361-367.
Academic lecture
  • Show author(s) (2010). Estrogen Receptor degradation.
  • Show author(s) (2005). Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG).
Reader opinion piece
  • Show author(s) (2013). Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 861-U216.
Masters thesis
  • Show author(s) (2010). CYP2C19 single nucleotide polymorphisms And their effects on the metabolism of Tamoxifen in breast cancer patients.
Doctoral dissertation
  • Show author(s) (2008). Tamoxifen treatment of breast cancer: Pharmacogenetics and therapeutic drug monitoring.
Academic chapter/article/Conference paper
  • Show author(s) (2018). Effect of Whey and Herring Roe Protein administered as a supplement to young healthy adults – A pilot study.
  • Show author(s) (2012). Tamoxifen metabolism and biological activity. 22 pages.
  • Show author(s) (2011). Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. 18 pages.
  • Show author(s) (2011). Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. 32 pages.
Abstract
  • Show author(s) (2013). Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 1 pages.
  • Show author(s) (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
  • Show author(s) (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Show author(s) (2007). Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
  • Show author(s) (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Show author(s) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Poster
  • Show author(s) (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
  • Show author(s) (2011). The nuclear receptors NURR77, NURR1 and NOR1 in obesity and during fat loss.
  • Show author(s) (2010). The influence of tamoxifen treatment on the expression levels of liver receptor homolog (LHR-1).
  • Show author(s) (2010). Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients.
  • Show author(s) (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism.
  • Show author(s) (2010). Distribution of tamoxifen and five metabolites into normal and malignant human breast cancer tissue during conventional and low dose treatment.
  • Show author(s) (2009). Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment.
  • Show author(s) (2007). Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients.
  • Show author(s) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment.
  • Show author(s) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Show author(s) (2005). Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Show author(s) (2005). Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route.
  • Show author(s) (2004). Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats.
  • Show author(s) (2004). Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry.
  • Show author(s) (2002). Tamoxifen metabolism in immunocompromised rats and mice.

More information in national current research information system (CRIStin)